Fierce Biotech

Moderna scraps congenital virus program after vaccine shows little protective effect in phase 3

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...
GlobalData on MSN

Moderna scraps mRNA vaccine in congenital CMV on Phase III failure

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...
Stocktwits on MSN

Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn

Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...
Investor's Business Daily on MSN

Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust

Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.
pharmaphorum

Moderna drops mRNA jab for CMV after phase 3 fail

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once ...